US 12,168,788 B2
FCE mRNA capping enzyme compositions, methods and kits
Mehul Ganatra, Gloucester, MA (US); Siu-Hong Chan, Ipswich, MA (US); Christopher H. Taron, Essex, MA (US); and G. Brett Robb, Somerville, MA (US)
Assigned to New England Biolabs, Inc., Ipswich, MA (US)
Filed by New England Biolabs, Inc., Ipswich, MA (US)
Filed on Jun. 23, 2023, as Appl. No. 18/340,083.
Application 17/246,454 is a division of application No. 17/160,256, filed on Jan. 27, 2021, granted, now 11,028,379.
Application 18/340,083 is a continuation of application No. 17/377,797, filed on Jul. 16, 2021, granted, now 11,725,196.
Application 17/377,797 is a continuation of application No. 17/246,454, filed on Apr. 30, 2021, granted, now 11,098,295.
Prior Publication US 2023/0416705 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/16 (2006.01); A61K 39/00 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 9/10 (2006.01); C12N 9/12 (2006.01)
CPC C12N 9/16 (2013.01) [A61K 39/245 (2013.01); C12N 7/00 (2013.01); C12N 9/1007 (2013.01); C12N 9/1241 (2013.01); C12Y 201/01056 (2013.01); C12Y 207/0705 (2013.01); C12Y 301/03033 (2013.01); A61K 2039/53 (2013.01); C07K 2319/21 (2013.01); C12N 2710/16134 (2013.01)] 16 Claims
 
1. An FCE variant having (a) an amino acid sequence at least 95% identical to positions 1 to 878 of SEQ ID NO: 1, and (b) a substitution relative to SEQ ID NO: 1 at a position corresponding to positions 215, 337, 572, 648, and/or 833 of SEQ ID NO: 1.